Physician

Internal Medicine

Darrell R. Abernethy works in the field of Internal Medicine. He attended University of Kansas School of Medicine. Darrell Abernethy is a published doctor. He published 39 publications, including: 'Linking MedDRA()-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.'

Publications

---

• Application of systems pharmacology to explore mechanisms of hepatotoxicity.
• The utility of modeling and simulation in drug development and regulatory review.
• Systems pharmacology to predict drug toxicity: integration across levels of biological organization.
• Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms.
• Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
• Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults.
• Geriatric drug evaluation: where are we now and where should we be in the future?
• Reducing drugs in older adults is more.
• Drug Burden Index and Beers Criteria: Impact on Functional Outcomes in Older People Living in Self-Care Retirement Villages.
• A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people.
• Serum protein signatures detect early radiographic osteoarthritis.
• Change in criteria for USP dissolution performance verification tests.
• Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.
• Measures of drug toxicity in older adults.
• Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities.
• Analysis of functional signaling domains from fluorescence imaging and the two-dimensional continuous wavelet transform.
• Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.
• Use of wavelet and fast Fourier transforms in pharmacodynamics.
• A drug burden index to define the functional burden of medications in older people.
• Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit.
• Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol.
• Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats.
• Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
• Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy.
• Differential role of the alpha1C subunit tails in regulation of the Cav1.2 channel by membrane potential, beta subunits, and Ca2+ ions.
• New short splice variants of the human cardiac Cavbeta2 subunit: redefining the major functional motifs implemented in modulation of the Cav1.2 channel.
• Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique.
• Voltage-gated rearrangements associated with differential beta-subunit modulation of the L-type Ca(2+) channel inactivation.
• Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.
• Kullback-Leibler clustering of continuous wavelet transform measures of heart rate variability.
• Effect of angiotensin-converting enzyme insertion/deletion polymorphism DD genotype on high-frequency heart rate variability in African Americans.
• Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
• Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction.
• Voltage-gated mobility of the Ca2+ channel cytoplasmic tails and its regulatory role.
• Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
• Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets.
• Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
• Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.

Schools

---

• University of Kansas School of Medicine

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Education

---

• Massachusetts General Hospital
• Jackson Memorial Hospital - Jackson Health System
• University of Kansas School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Gregory L. Walker, MD This Doctor is OpenDoctor Recommended.
	Dr. Susan H. Rubinstein, MD This Doctor is OpenDoctor Recommended.
	Dr. Rachael Oxman, MD This Doctor is OpenDoctor Recommended.
	Dr. Sosena Kebede, MD This Doctor is OpenDoctor Recommended.
	Dr. Abeyot D. Tegegne, MD This Doctor is OpenDoctor Recommended.
	Dr. Kavita Sharma, MD
	Dr. Sameep R. Sehgal, MD This Doctor is OpenDoctor Recommended.
	Boon Y. Tan, MB CHB
	Dr. Hirad Yarmohammadi, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog